In a recently published study, Liu et al. identified KDM7B as an oncogenic factor in KRAS- or BRAF-mutant CRC by genome-wide CRISPR screening, and targeting KDM7B significantly improved the efficacy of anti-PD1 therapy [172]. Here, KRAS is linked to colorectal carcinoma.